NCT06580041 - Precision Care for Major Depressive Disorder | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

September 1, 2029

Study Completion Date

September 1, 2029

Conditions

Major Depressive DisorderDepressionDepressive Disorder, Major

Interventions

DRUG

Pramipexole

CAU plan modified to include a trial of pramipexole.

DRUG

Methylphenidate

CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).

DRUG

Phenelzine

CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).

BEHAVIORAL

Mindfulness-based Stress Sensitivity Therapy (MBSST)

CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.

BEHAVIORAL

Complicated Grief Treatment (CGT)

CAU plan modified to include a trial of CGT.

OTHER

Care as usual (CAU) plan

Unmodified CAU plan.

Trial Locations (1)

Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco, San Francisco

All Listed Sponsors

lead

University of California, San Francisco

OTHER